Callagy et al. (2006) have also found that BCL-2 was the only marker from a panel of 13 proteins (HER2, c-Myc, cyclin E, CK5/6, CK17, CK8/18, ER, Ki-67, MCM-2, p27, P53 and PgR) that improved prognostication in the group of 930 breast cancer patients, some of whom were treated with adjuvant CT. This evidence concerns the gene MCM2 and breast carcinoma.